

AstraZeneca sues Aurobindo Pharma

HYDERABAD: AstraZeneca AB has sued Aurobindo Pharma Ltd in the District Court of Delaware, for alleged infringement of its patent on diabetic drug Onglyza, according to a US court document. In April, Aurobindo Pharma submitted an abbreviated new drug application with the US Food and Drug Administration for a generic of Onglyza in 2.5 and 5 mg dosages, with paragraph-IV certification. For the 12 months ending February, Onglyza had sales of around \$532 mn, according to IMS Health data.

Patent.